News | August 05, 2021
Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
The company has already embarked upon significant expansion in Turkey
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana
Subscribe To Our Newsletter & Stay Updated
